How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

795 results for

Cutaneous Candidiasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. (Abstract)

The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Toll-like receptors, a major component of the innate immune system, play an important role in the initial response against pathogens. Genetic abnormalities in some receptors like TLR2, TLR3 and TLR4 have been associated with susceptibility to fungal and viral infections while other aberrations in TLR genes such as TLR3, TLR7 and TLR9 may predispose to autoimmunity (...) . Recently we have shown an association of a TLR3 receptor variant, L412F, to susceptibility to chronic candidiasis, recurrent viral and bacterial infections and autoimmunity. We investigated here the biological implications of this TLR3 mutant.To study the functional impact of the L412F variant of TLR3 we tested patients' peripheral blood mononuclear cells (PBMCs) as well as fibroblasts for secretion of cytokines in response to TLR3 ligand, candida or cytomegalovirus (CMV). In addition, the P2.1 cell

2012 Autoimmunity reviews

42. Topical treatment of inflammatory dermatoses and cutaneous candidiasis with a new cortico-steroid -antibiotic combination: halcinonide-neomycin-amphotericin. (Abstract)

Topical treatment of inflammatory dermatoses and cutaneous candidiasis with a new cortico-steroid -antibiotic combination: halcinonide-neomycin-amphotericin. 326284 1977 08 12 2018 11 30 0007-0947 31 4 1977 Apr The British journal of clinical practice Br J Clin Pract Topical treatment of inflammatory dermatoses and cutaneous candidiasis with a new cortico-steroid -antibiotic combination: halcinonide-neomycin-amphotericin. 33-5, 39 Reyes-Javier P P eng Clinical Trial Journal Article Randomized (...) Controlled Trial England Br J Clin Pract 0372546 0007-0947 0 Anti-Inflammatory Agents 0 Drug Combinations 0 Glucocorticoids 0 Pregnenediones 7XU7A7DROE Amphotericin B I16QD7X297 Neomycin IM Administration, Topical Adolescent Adult Aged Amphotericin B therapeutic use Anti-Inflammatory Agents therapeutic use Candidiasis, Cutaneous drug therapy Child Child, Preschool Clinical Trials as Topic Dermatitis drug therapy Drug Combinations Female Glucocorticoids Humans Male Middle Aged Neomycin therapeutic use

1977 The British journal of clinical practice Controlled trial quality: uncertain

43. Familial chronic muco-cutaneous candidiasis. (Full text)

Familial chronic muco-cutaneous candidiasis. 4562433 1972 12 26 2018 11 13 0022-2593 9 3 1972 Sep Journal of medical genetics J. Med. Genet. Familial chronic muco-cutaneous candidiasis. 302-10 Wells R S RS Higgs J M JM Macdonald A A Valdimarsson H H Holt P J PJ eng Journal Article England J Med Genet 2985087R 0022-2593 11103-57-4 Vitamin A E1UOL152H7 Iron KV2JZ1BI6Z Pyridoxine IM Candida isolation & purification Candida albicans isolation & purification Candidiasis, Cutaneous complications (...) Candidiasis, Oral blood complications drug therapy etiology genetics immunology Chronic Disease Endocrine System Diseases complications Female Genes, Recessive Humans Iron blood Male Pedigree Pyridoxine blood Skin Tests Syndrome Vitamin A blood 1972 9 1 1972 9 1 0 1 1972 9 1 0 0 ppublish 4562433 PMC1469124 Lancet. 1970 Jun 13;1(7659):1259-61 4192497 Vitam Horm. 1964;22:591-607 14284121 J Lab Clin Med. 1953 Sep;42(3):335-57 13085024 Am J Med. 1968 Jun;44(6):979-89 4172913 Arch Dermatol. 1962 Feb;85:233-57

1972 Journal of Medical Genetics PubMed abstract

44. Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. (Full text)

Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Attempts were made to isolate an antigen(s) from Candida albicans suitable for detecting hypersensitivity in a murine model of candidiasis. Using footpad reactivity in cutaneously infected animals as the assay, comparisons were made of two commercial extracts and cell wall and cytoplasmic preparations made in the laboratory. An extract of the cell wall, a glycoprotein (GP) removed with ethylenediamine (...) , and an extract prepared from the membrane fraction of disrupted C. albicans blastospores proved most useful in demonstrating delayed hypersensitivity in the murine model. The activity of the GP fraction was considerably reduced by oxidation with periodate and was abrogated entirely by digestion with proteolytic enzymes. The extract from the membrane fraction was obtained by incubating the insoluble membrane fraction with phosphate-buffered saline, pH 7.4, at 50 degrees C, and the proteins in the extract were

1978 Infection and immunity PubMed abstract

45. Cutaneous candidiasis: treatment with miconazole nitrate. (Abstract)

Cutaneous candidiasis: treatment with miconazole nitrate. In a well-controlled, double-blind, randomized study, 30 patients with cutaneous candidiasis were treated with a 2% miconazole nitrate lotion or its placebo control. By the 14th day, 13 of the 15 patients [87%] treated with miconazole nitrate achieved clinical and mycologic cures. Only a single patient treated with the placebo lotion would be classified as a therapeutic cure. In a second portion of the study those patients judged

1977 Cutis; cutaneous medicine for the practitioner Controlled trial quality: uncertain

46. Evaluation of a topical steroid antibiotic combination (halcinonide-neomycin-amphotericin) in the treatment of cutaneous candidiasis and inflammatory dermatoses. (Abstract)

Evaluation of a topical steroid antibiotic combination (halcinonide-neomycin-amphotericin) in the treatment of cutaneous candidiasis and inflammatory dermatoses. Halcinonide-neomycin-amphotericin (HNA) cream was evaluated in the treatment of cutaneous candidiasis and inflammatory dermatoses. The anti-candidal properties of HNA were assessed in a parallel comparison with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The overall therapeutic response with HNA was excellent in 38

1979 Current medical research and opinion Controlled trial quality: uncertain

47. Cutaneous Yarrowia lipolytica infection in an immunocompetent woman (Full text)

Cutaneous Yarrowia lipolytica infection in an immunocompetent woman 28443314 2019 02 26 2352-5126 3 3 2017 May JAAD case reports JAAD Case Rep Cutaneous Yarrowia lipolytica infection in an immunocompetent woman. 219-221 10.1016/j.jdcr.2017.02.010 Boyd Alan S AS Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Pathology, Immunology, and Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (...) . Wheless Lee L Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Brady Bobbi G BG Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Ellis Darrel D Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. eng Case Reports 2017 04 14 United States JAAD Case Rep 101665210 2352-5126 Candida Yarrowia lipolytica catheter eschar

2017 JAAD Case Reports PubMed abstract

48. Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions (Full text)

Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions Cutaneous leishmaniasis (CL) generally presents with a single or several localised cutaneous ulcers without involvement of mucous membranes. Ulcerated lesions are susceptible to secondary contamination that may slow the healing process.This study verified the influence of non-parasitic wound infection on wound closure (epithelialisation) and total healing.Twenty-five patients with a confirmed (...) diagnosis of CL and ulcerated lesions underwent biopsy of ulcer borders. One direct microbial parameter (germ identification in cultures) and four indirect clinical parameters (secretion, pain, burning sensation, pruritus) were analysed. FINDINGS Biopsies of ten lesions showed secondary infection by one or two microorganisms (Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, Streptococcus pyogenes and Candida parapsilosis). "Secretion" and "burning sensation" influenced

2017 Memórias do Instituto Oswaldo Cruz PubMed abstract

49. Frequency of Cutaneous Fungal Infections and Azole Resistance of the Isolates in Patients with Diabetes Mellitus (Full text)

with diabetic foot ulcer and 28% of patients with skin and nail lesions. Candida albicans and Aspergillus flavus were the most common species isolated from thirty patients with fungal infection, respectively. Susceptibility testing carried out on 18 representative isolates (13 C. albicans, five C. glabrata) revealed that 12 isolates (10 C. albicans and two C. glabrata isolates) (66.6%) were resistant (minimum inhibitory concentration [MIC] ≥64 mg/ml) to fluconazole (FCZ). Likewise, eight isolates (80 (...) Frequency of Cutaneous Fungal Infections and Azole Resistance of the Isolates in Patients with Diabetes Mellitus Diabetic patients are more susceptible to cutaneous fungal infections. The higher blood sugar levels cause increasing the cutaneous fungal infections in these patients. The main objective of this study was to find the frequency of fungal infections among cutaneous lesions of diabetic patients and to investigate azole antifungal agent susceptibility of the isolates.In this study, type

2017 Advanced biomedical research PubMed abstract

50. A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03259620

2017 Clinical Trials

51. Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03041025 Recruitment Status : Recruiting First Posted : February 2, 2017 Last Update Posted

2017 Clinical Trials

52. Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria:- patients with ages ranging from 10 to 40 years with cutaneous common or planter wart , or were either resistant to treatment or had relapsed at least once after treatment with any of the tissue-destructive modalities Exclusion Criteria:.- Patients with any evidence of immunosuppressant, eczematous skin disorder, those with any history of hypersensitivity to Candida albicans antigen, pregnant or lactating women (...) . Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c. Drug: Candida Antigen Candida Albicans Antigen injection Active Comparator: control group The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may

2017 Clinical Trials

53. A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. (Full text)

A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis. Many of the molecular pathways associated with psoriasis pathogenesis are also involved in host defense mechanisms that protect against common pathogens. Candida can stimulate the production of cytokines that trigger or exacerbate psoriasis, and many systemic psoriasis treatments may put patients at increased risk for developing oral, cutaneous, and genitourinary candidiasis. Therefore, dermatologists (...) should regularly screen patients with psoriasis for signs of Candida infection, and take steps to effectively treat these infections to prevent worsening of psoriasis symptoms. This review provides an overview of candidiasis epidemiology in patients with psoriasis, followed by a primer on the diagnosis and treatment of superficial Candida infections, with specific guidance for patients with psoriasis. Candidiasis in patients with psoriasis typically responds to topical or oral antifungal therapy

2016 American journal of clinical dermatology PubMed abstract

54. Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity (Full text)

Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity 5442521 1970 06 19 2018 11 13 0009-9104 6 3 1970 Mar Clinical and experimental immunology Clin. Exp. Immunol. Chronic mucocutaneous moniliasis with impaired delayed hypersensitivity. 375-85 Kirkpatrick C H CH Chandler J W JW Schimke R N RN eng Journal Article England Clin Exp Immunol 0057202 0009-9104 0 Antigens IM Adrenal Insufficiency immunology Antibody Formation Antigens Candida immunology Candidiasis, Cutaneous

1970 Clinical and experimental immunology PubMed abstract

55. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution (Full text)

Autoantibodies analysis Blood Donors Blood Transfusion Candida albicans Candidiasis diagnosis immunology therapy Candidiasis, Cutaneous therapy Candidiasis, Oral therapy Cell Migration Inhibition Chronic Disease Humans Hypersensitivity, Delayed Immunity, Cellular Lymphocytes immunology metabolism Macrophages Male Skin Tests Thymidine metabolism Tritium 1971 12 1 2001 3 28 10 1 1971 12 1 0 0 ppublish 4945734 PMC1713127 Lancet. 1970 Jun 13;1(7659):1259-61 4192497 J Immunol. 1970 Jan;104(1):95-102 5411506 J (...) Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution 4945734 1972 04 21 2018 11 13 0009-9104 9 6 1971 Dec Clinical and experimental immunology Clin. Exp. Immunol. Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. 733-48 Kirkpatrick C H CH Rich R R RR Graw R G RG Jr Smith T K TK Mickenberg I I Rogentine G N GN eng Journal Article England Clin Exp Immunol 0057202 0009-9104 0 Autoantibodies 10028-17-8 Tritium VC2W18DGKR Thymidine IM Adolescent

1971 Clinical and experimental immunology PubMed abstract

56. Moniliasis, `autoimmune' polyendocrinopathy, and immunologic family study (Full text)

Moniliasis, `autoimmune' polyendocrinopathy, and immunologic family study 6030796 1967 09 26 2018 11 13 0009-9104 2 1 1967 Jan Clinical and experimental immunology Clin. Exp. Immunol. Moniliasis, 'autoimmune' polyendocrinopathy, and immunologic family study. 71-82 Wuepper K D KD Fudenberg H H HH eng Case Reports Journal Article England Clin Exp Immunol 0057202 0009-9104 IM Adrenal Insufficiency complications Adult Autoimmune Diseases diagnosis genetics Candidiasis, Cutaneous complications

1967 Clinical and experimental immunology PubMed abstract

57. Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow (Full text)

Hattler B G BG Jr Zmijewski C M CM Amos D B DB eng Journal Article England Clin Exp Immunol 0057202 0009-9104 0 Antibodies 0 Lectins 0 gamma-Globulins 63231-63-0 RNA IM Adolescent Antibodies analysis Bone Marrow Transplantation Candida immunology Candidiasis, Cutaneous immunology therapy Child Female Humans Hypersensitivity, Delayed Hypersensitivity, Immediate In Vitro Techniques Lectins pharmacology Lymphocytes drug effects Male RNA biosynthesis Saliva immunology Skin Diseases, Infectious immunology (...) Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow 4171049 1968 05 09 2018 11 13 0009-9104 3 2 1968 Feb Clinical and experimental immunology Clin. Exp. Immunol. Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. 153-69 Buckley R H RH Lucas Z J ZJ

1968 Clinical and experimental immunology PubMed abstract

58. Thrush

areas of the body and is generally caused by Candida albicans; includes chronic mucocutaneous candidiasis, cutaneous candidiasis, oral candidiasis (thrush), and monilial vaginitis. Concepts Disease or Syndrome ( T047 ) MSH ICD9 112.9, 112 ICD10 , SnomedCT 187005005 , 187024008 , 187478002 , 154403005 , 370520002 , 78048006 English Candidiases , Candidiasis , Moniliases , Moniliasis , CANDIDIASIS , MONILIASIS , Candidiasis, unspecified , [X]Candidiasis, unspecified , candidiasis , candidiasis (...) (diagnosis) , Candida infections , Candidiasis site NOS , candidosis , Candidiasis [Disease/Finding] , candidal infection , candidal infections , monilial infection , thrush , candida infections , candidiases , candida infection , muguet , monilia infection , Candidiasis NOS (disorder) , [X]Candidiasis, unspecified (disorder) , Candida NOS , Monilial infection , Moniliasis monilia , Moniliasis NOS , Candidiasis of unspecified site , Monilia NOS , Candidal infection NOS , Candidiasis NOS , Thrush

2015 FP Notebook

59. Use of cost effective and rapid molecular tools for identification of Candida species, opportunistic pathogens (Full text)

assay and amplification of hwp1 gene.Clinical samples comprising of vaginal specimens ,cutaneous, sputum, bronchoalveolar lavage(BAL,( and blood cultures were recovered from suspected patients. Candida isolates were initially identified phenotypically and confirmed by molecular approaches based on restriction fragment length polymorphism (PCR-RFLP (with MspI restriction enzyme. Amplification of hwp1 gene was performed for discrimination of C. albicans from C. dubliniensis and C.africana.The most (...) Use of cost effective and rapid molecular tools for identification of Candida species, opportunistic pathogens Candidiasis is a widespread fungal infection caused by different Candida species. Rapid identification of Candida species in clinical laboratory is becoming increasingly important since the identification and discrimination of ethological agents for early treatment. We aimed at molecular identification of commonly Candida species isolated from clinical samples by using both PCR-RFLP

2016 Current Medical Mycology PubMed abstract

60. Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience. (Abstract)

data indicate that intralesional Candida antigen therapy for cutaneous warts is an efficacious option in a clinical practice setting. The treatment may also be effective in immunosuppressed patients with cutaneous warts. Our results add to the literature one of the largest retrospective series reported to date and treatment outcomes are similar to previously reported studies evaluating this therapeutic modality. (...) Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience. Common warts (verruca vulgaris) are one of the most common problems encountered in dermatology and may present a difficult treatment dilemma, as no particular therapy has demonstrated complete efficacy. Intralesional injection of purified Candida antigen has produced impressive treatment results in small prospective and retrospective studies and is thought to produce its effect through

2015 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>